[Correspondence] Antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against SARS-CoV-2 omicron subvariants including JN.1, KP.3.1.1, and XEC

Di |2024-12-11T00:30:01+01:00Dicembre 11th, 2024|Categorie: Coronavirus Lancet|

As of November, 2024, SARS-CoV-2 omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2),1 KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC2—a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3)—have been circulating in seve...

[Articles] Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children

Di |2024-12-11T00:30:00+01:00Dicembre 11th, 2024|Categorie: Coronavirus Lancet|

RH5.1/Matrix-M appears safe and highly immunogenic in African children and shows promising efficacy against clinical malaria when given in a delayed third-dose regimen. This trial is ongoing to further monitor efficacy over time.

[Comment] Will a new pentavalent meningococcal ABCWY vaccine mark a milestone in protecting all those at risk from invasive meningococcal disease?

Di |2024-12-06T00:30:03+01:00Dicembre 6th, 2024|Categorie: Coronavirus Lancet|

The publication of a phase 3 trial by Terry Nolan and colleagues in The Lancet Infectious Diseases marks a key step towards licensing a new GSK vaccine (MenABCWY) which targets five Neisseria meningitidis serogroups.1 The vaccine combines a conjugate v...

[Articles] Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial

Di |2024-12-06T00:30:01+01:00Dicembre 6th, 2024|Categorie: Coronavirus Lancet|

This study demonstrates breadth of immune response against a panel of 110 MenB strains for the MenB component of the investigational MenABCWY vaccine, when administered as a 0–6 months schedule to the target population of adolescents and young adults, ...

[Review] Barriers and facilitators to the implementation of electronic monitors to improve adherence and health outcomes in patients with tuberculosis: a systematic review

Di |2024-11-30T00:30:01+01:00Novembre 30th, 2024|Categorie: Coronavirus Lancet|

Tuberculosis remains a public health concern, and electronic monitors show promise in improving treatment adherence and health outcomes among patients with tuberculosis. This Review aims to provide a comprehensive understanding of the implementation ba...

Torna in cima